CA2068069C - Blood coagulation factor xi concentrate having high specific activity, suitable for therapeutic use, and process for preparing same - Google Patents

Blood coagulation factor xi concentrate having high specific activity, suitable for therapeutic use, and process for preparing same Download PDF

Info

Publication number
CA2068069C
CA2068069C CA002068069A CA2068069A CA2068069C CA 2068069 C CA2068069 C CA 2068069C CA 002068069 A CA002068069 A CA 002068069A CA 2068069 A CA2068069 A CA 2068069A CA 2068069 C CA2068069 C CA 2068069C
Authority
CA
Canada
Prior art keywords
factor
process according
filter
sodium chloride
concentrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002068069A
Other languages
English (en)
French (fr)
Other versions
CA2068069A1 (en
Inventor
Miryana Burnouf
Dominique Dernis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
Association pour lEssor de la Transfusion Sanguine dans la Region Nord
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Association pour lEssor de la Transfusion Sanguine dans la Region Nord filed Critical Association pour lEssor de la Transfusion Sanguine dans la Region Nord
Publication of CA2068069A1 publication Critical patent/CA2068069A1/en
Application granted granted Critical
Publication of CA2068069C publication Critical patent/CA2068069C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6443—Coagulation factor XIa (3.4.21.27)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21027—Coagulation factor XIa (3.4.21.27)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA002068069A 1991-05-07 1992-05-06 Blood coagulation factor xi concentrate having high specific activity, suitable for therapeutic use, and process for preparing same Expired - Lifetime CA2068069C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9105572 1991-05-07
FR9105572A FR2676231A1 (fr) 1991-05-07 1991-05-07 Concentre de facteur xi de la coagulation sanguine a haute activite specifique, approprie a usage therapeutique et son procede de preparation.

Publications (2)

Publication Number Publication Date
CA2068069A1 CA2068069A1 (en) 1992-11-08
CA2068069C true CA2068069C (en) 2005-03-15

Family

ID=9412593

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002068069A Expired - Lifetime CA2068069C (en) 1991-05-07 1992-05-06 Blood coagulation factor xi concentrate having high specific activity, suitable for therapeutic use, and process for preparing same

Country Status (16)

Country Link
US (1) US5252217A (OSRAM)
EP (1) EP0512883B1 (OSRAM)
AT (1) ATE156360T1 (OSRAM)
AU (1) AU652043B2 (OSRAM)
BR (1) BR9201718A (OSRAM)
CA (1) CA2068069C (OSRAM)
DE (1) DE69221369T2 (OSRAM)
DK (1) DK0512883T3 (OSRAM)
EE (1) EE03017B1 (OSRAM)
ES (1) ES2107511T3 (OSRAM)
FR (1) FR2676231A1 (OSRAM)
GR (1) GR3025134T3 (OSRAM)
IL (1) IL99567A (OSRAM)
LT (1) LT3417B (OSRAM)
RU (1) RU2097047C1 (OSRAM)
UA (1) UA27733C2 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2151604C1 (ru) * 1999-01-21 2000-06-27 Станкевич Виктор Евгеньевич Способ приготовления универсальной гемотрансфузионной среды
AU2002354846B2 (en) * 2001-07-20 2007-08-02 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
KR20060118486A (ko) * 2003-11-20 2006-11-23 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｘｉ의 치료적 사용
US20050181978A1 (en) * 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
WO2006128497A1 (en) * 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
CL2007002615A1 (es) * 2006-09-08 2008-04-18 Wyeth Corp Metodos para aislar o purificar un producto que comprende poner el producto enlazado en contacto con al menos una solucion de lavado que comprende arginina y luego eluir el producto; y dicho producto.
ATE546520T1 (de) * 2007-01-04 2012-03-15 Crucell Holland Bv Faktor-xi-reinigung
CN104212799B (zh) 2008-10-15 2018-11-23 Ionis制药公司 因子11表达的调节
FR2974301B1 (fr) * 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2974366B1 (fr) * 2011-04-20 2016-06-24 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur xi
IL212911A0 (en) 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
DE102012022234A1 (de) 2012-11-14 2014-05-15 Instraction Gmbh Einstufiges Verfahren zur Reinigung von (Blut)Plasmaproteinen wie Albumin aus Gemischen
DE102012022233A1 (de) 2012-11-14 2014-05-15 Instraction Gmbh Verfahren zur Reinigung eines (Blut)plasmaproteins
FR3032621A1 (fr) 2015-02-13 2016-08-19 Lab Francais Du Fractionnement Colle biologique et son utilisation comme medicament
KR101941974B1 (ko) * 2016-11-18 2019-01-24 주식회사 녹십자 혈장 단백질 정제시 fxi의 제거방법
US20210355497A1 (en) 2018-05-09 2021-11-18 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing fxi expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859340A (en) * 1976-03-15 1989-08-22 Cuno, Incorporated Filter sheet
US4783262A (en) * 1987-03-30 1988-11-08 Cuno Incorporated Separator for cell type filter element

Also Published As

Publication number Publication date
ATE156360T1 (de) 1997-08-15
EP0512883A1 (fr) 1992-11-11
EE03017B1 (et) 1997-08-15
CA2068069A1 (en) 1992-11-08
LT3417B (en) 1995-09-25
RU2097047C1 (ru) 1997-11-27
BR9201718A (pt) 1992-12-29
AU652043B2 (en) 1994-08-11
IL99567A (en) 1996-01-19
DE69221369D1 (de) 1997-09-11
DE69221369T2 (de) 1998-03-19
UA27733C2 (uk) 2000-10-16
IL99567A0 (en) 1992-08-18
FR2676231A1 (fr) 1992-11-13
DK0512883T3 (da) 1998-03-16
FR2676231B1 (OSRAM) 1995-04-21
AU1526392A (en) 1992-11-12
EP0512883B1 (fr) 1997-08-06
ES2107511T3 (es) 1997-12-01
US5252217A (en) 1993-10-12
GR3025134T3 (en) 1998-02-27
LTIP265A (en) 1994-10-25

Similar Documents

Publication Publication Date Title
CA2068069C (en) Blood coagulation factor xi concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
JP3094167B2 (ja) 免疫血清グロブリンの精製方法
KR100451266B1 (ko) 새로운크로마토그래피분리조건을이용한α-1프로테이나제억제제의정제방법
AU621148B2 (en) Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
RU1837880C (ru) Способ разделени белков крови
EP0556083B1 (en) Process for the production of biologically active substances from milk and related raw materials
CA2024667C (en) Process for preparing a concentrate of blood coagulation factor viii-von willebrand factor complex from total plasma
JPH03128398A (ja) 血漿蛋白の分画方法
EP0239565B1 (en) Method of separating proteins
EP1519944B1 (en) Processes for the preparation of fibrinogen
US4137127A (en) Process for the preparation of thrombin-like enzymes from snake venoms
CA2621025A1 (en) An ultra-high yield intravenous immune globulin preparation
US4774323A (en) Purification of von Willebrand Factor solutions using gel permeation chromatography
AU2006287833B2 (en) An ultra-high yield intravenous immune globulin preparation
KR100361894B1 (ko) 치환크로마토그라피방법및정제된헤모글로빈생성물
CA1216792A (en) Method of inactivating incompatibility-reaction- causing substances
CA1341379C (en) Purified antithrombin-iii and methods of producing the same
US5681750A (en) Process for preparing a C1-esterase inhibitor concentrate (C1-INH), and concentrate obtained, for therapeutic use
US5989593A (en) Method for producing antithrombin-III, method for purifying it, and preparation containing it
EP0041174B1 (en) Blood coagulation promoting product and process of preparing same
LV10194B (en) Blood coagulation factor xi concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
CN114395032B (zh) 一种从血浆中提取人抗凝血酶ⅲ的方法
UA151581U (uk) Спосіб одержання комплексного препарату фактора зсідання крові viii
KR19980042603A (ko) 안티트롬빈-ⅲ의 제조방법, 이의 정제방법 및 이를 함유하는제제
HUE025551T2 (en) A method of producing virus-inactivated FV concentrate starting from human plasma, which can be increased to industrial sizes

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry